Aurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 44607.51 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 30-06-2021, the company reported a Consolidated Total Income of Rs 5783.29 Crore, down -4.87 % from last quarter Total Income of Rs 6079.60 Crore and down -4.26 % from last year same quarter Total Income of Rs 6040.37 Crore. Company reported net profit after tax of Rs 778.97 Crore in latest quarter.
Investment Rationale
The brokerage values ARBP at 14x its 12-month forward earnings to arrive at TP of INR900. ARBP’s efforts are underway a) to enhance product offerings comprising Oncology, Hormones, Depot Injections, Inhalers, Biosimilars, Topicals, and Patches, and b) improving margin in the EU business.
Promoter/FII Holdings
Promoters held 51.8 per cent stake in the company as of June 30, 2021, while FIIs held 23.7 per cent, DIIs 14.7 per cent and public and others 9.8 per cent.
(Disclaimer: Views and recommendations given in this section are the analysts’ own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.
